KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EBITDA Margin for 15 consecutive years, with 6.82% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 2257.0% year-over-year to 6.82%, compared with a TTM value of 9.0% through Dec 2025, up 2186.0%, and an annual FY2025 reading of 8.84%, up 2170.0% over the prior year.
  • EBITDA Margin was 6.82% for Q4 2025 at Alnylam Pharmaceuticals, down from 24.09% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 24.09% in Q3 2025 and bottomed at 154.17% in Q3 2022.
  • Average EBITDA Margin over 5 years is 55.39%, with a median of 57.49% recorded in 2022.
  • The sharpest move saw EBITDA Margin surged 17449bps in 2023, then tumbled -5676bps in 2025.
  • Year by year, EBITDA Margin stood at 99.6% in 2021, then surged by 38bps to 62.19% in 2022, then surged by 53bps to 29.32% in 2023, then soared by 46bps to 15.76% in 2024, then soared by 143bps to 6.82% in 2025.
  • Business Quant data shows EBITDA Margin for ALNY at 6.82% in Q4 2025, 24.09% in Q3 2025, and 7.59% in Q2 2025.